Complications of thrombopoietin receptor agonists therapy in patients with immune thrombocytopenia

Autor: S. G. Zakharov, T. A. Mitina, A. V. Zakharova, O. P. Madzyara, I. N. Kontievskii, R. V. Vardanyan, E. V. Kataeva, Yu. B. Chernykh, L. L. Vysotskaya, L. V. Ivanitskiy, Yu. Yu. Chuksina, O. R. Zhuravlev, N. V. Gorgun, Z. M. Kharasova, E. V. Trifonova, K. A. Belousov, Z. R. Tekeeva
Jazyk: ruština
Rok vydání: 2024
Předmět:
Zdroj: Онкогематология, Vol 19, Iss 2, Pp 109-117 (2024)
Druh dokumentu: article
ISSN: 1818-8346
2413-4023
DOI: 10.17650/1818-8346-2024-19-2-109-117
Popis: Immune thrombocytopenia (ITP) is an autoimmune disease characterized by increased platelet destruction and decreased platelet production. The formation of antibodies to platelet and megakaryocyte glycoproteins plays a major role in the pathophysiology of ITP. All treatment strategies for ITP attempt to increase platelet count and reduce the risk of bleeding complications. Corticosteroids remain the most commonly used first-line therapy for ITP, but their long-term use is limited due to the development of severe complications. Today the new treatment methods including the use of thrombopoietin receptor agonists (TPO-RA) romiplostim, eltrombopag and avatrombopag with a number of advantages over standard therapy are of great interest. These drugs are recommended for use in the second-line therapy and show high efficacy in patients with ITP, particularly in real clinical practice. In most cases TPO-RA provide stable and long-term remission of the disease, allowing you to reduce or discontinue the use of glucocorticosteroids and avoid splenectomy. Many studies of the mechanism of action, efficacy and toxicity of TPO-RA have been performed. the research results significantly expand our knowledge about these agents. This review provides comparative data of the TPO-RA safety and the main aspects of their clinical use. The features of the new drug avatrombopag, recently approved for use in the Russian federation, are described. the overview presents the advantages and limitations of each drug, possible adverse events and methods for their control.
Databáze: Directory of Open Access Journals
Externí odkaz: